Context: Elevated temperature worsens injury in experimental focal and global ischemia and brain trauma. Fever is common in patients with acute neurologic illness and independently predicts poor outcome. Conventional means of treating fever are not very effective in this population.
levated temperature worsens outcome in experimental models of cerebral ischemia and brain trauma; this is associated with increased levels of excitotoxins and oxygen radicals, destabilization of cell membranes, and increased number of abnormal electrical depolarizations (1) (2) (3) (4) (5) . Even an increase in temperature of 0.5°C results in a greater zone of injury and neuronal loss (5) (6) (7) (8) . Fever is common in critically ill neurologic and neurosurgical patients, and its causes include not only infections but also the release of endogenous pyrogens due to neuronal injury or the presence of blood in the cerebral parenchymal, ventricles, and subarachnoid space.
Fever is an independent predictor of poor outcome in patients with ischemic stroke, intracerebral hemorrhage and subarachnoid hemorrhage (9 -14) . The impact of fever control on clinical outcome, however, has not yet been tested, in large part due to the lack of an effective means to control fever. Despite this, taking measures to reduce fever is recommended by guidelines for the management of ischemic stroke, intracerebral hemorrhage, subarachnoid hemorrhage, and traumatic brain injury (15) (16) (17) (18) . The most commonly used antipyretic is acetaminophen, although aspirin, ibuprofen, or indomethacin are used when the risk of bleeding is considered low.
Acetaminophen is not very effective at preventing or reducing fever. When highdose acetaminophen was given prospectively to ischemic stroke patients, the average temperature during the first 24 hrs after admission was 0.4°C lower than placebo-treated patients and no different after 5 days (19) . In a prospective, randomized study of 220 febrile neurologic intensive care unit (ICU) patients, half were treated with acetaminophen and half with acetaminophen plus air-cooled blanket therapy. In the acetaminophen group about one third of patients remained febrile, and the air-cooled blanket did not improve fever control (20) .
Physical means used to lower temperature include surface cooling with water or air-filled cooling blankets, ice packs, nasogastric or rectal lavage, and alcohol baths. These methods may have limited efficiency due to skin vasoconstriction and shivering. In one study, (20) 12% of patients refused or were unable to tolerate the air-cooled blanket therapy. External cooling with rotary fans, cooling blankets, and alcohol sponge baths are also time consuming and challenging for the nursing staff (21) . The goal of this study was to test the hypothesis that in neurologic ICU patients, an intravascular catheter-based cooling system was more effective in controlling fever than conventional means.
MATERIALS AND METHODS
The Neurocritical Care Fever Reduction Trial Group performed an Investigational Device Exemption Study (G990263) to evaluate the CoolGard/Cool Line catheter system (Alsius, Irvine, CA). The study was conducted in compliance with all Food and Drug Administration regulations with the approval of each participating center's institutional review board. Written informed consent was obtained in all cases. This study follows a successful feasibility study and publication of systems performance (22) .
Patients Ͼ17 yrs of age were eligible if they a) had a persistent fever (temperature of Ͼ38°C for 4 continuous hrs or two temperature spikes of Ͼ38°C within 72 hrs, the second occurring within 4 hrs of enrollment); b) clinically required central venous access; and c) were admitted with a diagnosis of subarachnoid hemorrhage, intracerebral hemorrhage, traumatic brain injury (Glasgow Coma Scale score Ͻ10), or ischemic stroke (National Institutes of Health Stroke Scale score Ͼ7).
Patients with the following were excluded: hypothermia (core temperature Ͻ36.5°C), active sepsis, spinal cord injury, active cardiac dysrhythmia with hemodynamic instability (determined by enrolling physician), pregnancy, use of barbiturate coma, use of Ͼ325 mg/day of aspirin, or if the patient was unlikely to remain in the ICU for 72 hrs.
Sample size was calculated using PASS 6.0 (Power and Sample Size Calculator, Number Cruncher Statistical Systems, Kaysville, UT) based on a 20-patient randomized investigational pilot study (22) that estimated fever burden in the control group to be 9.27 Ϯ 8.5°C-hrs (mean Ϯ SD); the hypothesis that the catheter would result in a 30% reduction in fever burden; a type I error of 0.05; and a statistical power of 80%. The sample size was calculated to be 111 patients in each group. The final sample size was increased to 148 patients per group for a total of 296 patients to account for possible incomplete data collection defined as missing temperature measurements for Ͼ4 consecutive hrs or a total duration of temperature measurements Ͻ65 hrs.
Design. Randomization was determined using computer-generated group assignment. Patients were block randomized 1:1 based on diagnosis and study site to either the control group (CON) or catheter group (CATH). Both cohorts were treated using a standardized fever management protocol (Table 1) , and the CATH cohort was also treated with the CoolGard/Cool Line catheter system for 72 hrs. The catheter could continue to be used for up to 7 days. The patient's bladder temperature was continuously monitored and recorded hourly during the study. All data were subjected to a 100% audit, which verified that the reported data agreed with source documents.
Device. The CoolGard/Cool Line catheter system has three components: the CoolGard external heat exchange and control unit, the Cool Line Catheter heat exchange catheter, and the Start-up Kit tubing set. The 8.5-Fr Cool Line intravascular heat exchanger catheter simultaneously functions as a single-or double-lumen central venous catheter. It is placed in the subclavian jugular or femoral vein using standard techniques. Normal saline is pumped from the CoolGard unit, via the tubing set, through two balloons coaxially mounted on the catheter in a closed loop that returns the saline to the CoolGard system. The CoolGard alters the temperature of the circulating saline to maintain the patient's temperature at a programmed value. Heat is transferred from the blood to the saline inside the balloon. With appropriate settings, the Cool Line intravascular heat exchange catheter has a cooling power of 60 W and can achieve cooling rates of up to 2.5°C/hr.
Patient Management and Monitoring. Baseline chest radiograph and blood, urine, and sputum cultures were obtained at the time of enrollment. White blood cell count was monitored daily. Additional cultures were obtained and a chest radiograph performed if the white blood cell count rose by 20% or temperature exceeded 38.0°C. Ventilator warming device temperatures were maintained at 37°C. Antipyretic medications not listed in the fever management protocol were avoided. Due to the very low frequency of shivering in earlier studies, no standardized treatment was required.
All adverse events were reported by the local principal investigator along with their assessment as to the relationship to the study device. The safety monitoring committee independently reviewed these assessments. All deaths were review by an independent review board, which was blinded to treatment.
End Points. The primary effectiveness end point in this study was total fever burden during the first 72 hrs of treatment. The fever burden was calculated, based on previously established methodology for assessment of antipyretic therapy, as the product of the fever and its duration (23) (24) (25) (26) . An example of the fever burden in an individual patient from each group is depicted in Figure 1 . Fever burden between the two cohorts was compared using a logarithmic scale to account for the curtailed normal distribution of the recorded patient temperatures above 38°C. The use of antipyretics, surfacecooling devices, and antibiotics and the frequency of infections was recorded. The safety of the product was assessed by prospectively monitoring for the following complications: death from any cause, pneumothorax or hemothorax related to central catheter placement, bacteremia, cardiac arrhythmias, pulmonary embolus, myocardial infarction, and thrombocytopenia.
Analysis. An intention to treat analysis was performed that included all enrolled patients. Missing serial measurements were interpolated based on the last and first observations bracketing the interval of the missing measure(s). If a patient ceased therapy before 72 hrs, the patient's average fever burden over the available time was used to extrapolate to 72 hrs. Incomplete temperature data were defined as Ն4 consecutive hrs of missing data or Ͻ65 total hrs of data.
Fever burden in the two groups was compared using a two-tailed Student's t-test for independent groups. The frequency of complications between groups was compared using the chi-square or Fisher's exact test, as appropriate. The mortality between groups was compared as a secondary end point using univariate analyses and logistic regression. The initial model included the following baseline variables: etiology (traumatic brain injury, intracerebral hemorrhage, subarachnoid hemorrhage, and ischemic stroke), race (white vs. nonwhite), blood pressure, pulse, sex, Glasgow 
RESULTS
A total of 296 patients were enrolled from June 2000 to March 2002. One patient was lost to follow-up. The perprotocol population included 238 patients. Sixteen patients were excluded because they did not meet the entry criteria or because of protocol violations. One patient was withdrawn by the attending physician. An additional 53 patients with incomplete data were excluded due to early death, prolonged time out of the ICU for diagnostic tests or procedures, or incomplete data collection (Figure 2) .
Baseline Characteristics. The majority of the enrolled patients had subarachnoid hemorrhage, followed by traumatic brain injury, intracerebral hemorrhage, and ischemic stroke. The two cohorts did not differ with respect to any baseline variables (Table 2) . Cool Line catheters were placed in the subclavian (73%), internal jugular (15%), and femoral (12%) veins with similar distributions of insertion sites for the two cohorts.
Fever Burden. The CATH group demonstrated reduced fever burden in both the intention to treat and per-protocol populations (Table 3) . There was also lower use of antipyretic agents, other means of fever management, sedatives, or narcotics (Table 4) . No other clinical or demographic factors were significantly related to fever burden. The differences between treatment groups were consistent among study sites.
Infections. There was no difference in the frequency of any infection between groups ( Table 5 ). The use of antibiotics was similar in the two groups.
Safety Analysis. The two groups did not significantly differ in mortality, major adverse events, or minor adverse events. Complications directly attributable to the placement of a central venous catheter did not differ between groups and were within Society of Cardiovascular and Interventional Radiology guidelines (27) (Table 5) . One multiple-trauma CATH patient with a Glasgow Coma Scale score of 3 died after open thrombectomy for a venous clot that occurred distal to the site of femoral catheter insertion. One unanticipated adverse event was reported along with other device-related issues that resulted in design and labeling changes. This event did not involve significant patient injury.
The groups did not differ in terms of 30-day cardiovascular, gastrointestinal, pulmonary, hematologic, renal, or neurologic complications. Shivering was noted to be of concern in four patients (3.7%). In these patients, shivering was managed by primarily sedation or by manipulation of the cooling rate.
Thirty-four CATH and 21 CON patients died (p ϭ .14). In none of the disease states was the difference in mortality significantly different. No deaths were judged to be device related by the reporting primary investigator or the data safety review board. The independent mortality review board determined that deaths were primarily due to the progression of the primary illness and frequently occurred as a result of the withdrawal of life-sustaining interventions (Table 6 ). Most patients died after the 72-hr temperature control period. No systematic causal device-related mechanism of injury was identified.
Logistic regression models were developed to determine whether the use of the catheter system was related to mortality. The variables included in the model were age, disease state, race (white vs. nonwhite), diastolic blood pressure, systolic blood pressure, pulse rate, sex, Glasgow Coma Scale score (Յ7 vs. Ͼ7), body weight, body mass index, and treatment group. No variables were identified within the logistic regression that predicted mortality other than age (p ϭ .003) and baseline Glasgow Coma Scale score (p ϭ .003).
DISCUSSION
Fever is common in the neurologic ICU, and conventional methods of cooling patients with antipyretics and surface cooling devices are not very effective. Recently, intravascular catheter-based cooling systems have been introduced as an alternative means of lowering body temperature. In this randomized, controlled trial, the use of the Cool Line/CoolGard system was more than twice as effective as conventional means in reducing fever burden.
The use of the intravascular catheter was not associated with an increase in complications greater than those associated with the use of a conventional central venous catheter. Despite concern that the use of the catheter could result in the failure to diagnose and treat infections, this was not the case. The 30-day infection rate and use of antibiotics (the catheter was used for a maximum of 7 days) was the same in both groups. It is highly unlikely that infections were missed because the protocol required the daily monitoring of the peripheral white blood cell count and collection of cultures if the peripheral white blood cell count rose by 20% or if temperature exceeded 38°C.
Shivering resulted primarily from a reduction in skin temperature. If the tubing set was not in direct contact with patient skin, shivering was uncommon in patients in the CATH group. It is important to note, however, that most of the patients in this study were intubated and sedated, which may have reduced the rate of shivering.
The primary end point chosen for this study was fever burden, not outcome. The purpose was to demonstrate the ability of the device to effectively treat fever in a broad population of neurologic ICU patients. Because of the heterogeneity of this population, the study was not powered to assess the impact of the device or of fever control on ultimate outcome. Now that an effective tool is available for treating fever in this population, an outcome study is possible and should be performed.
Although numerically higher in the catheter cohort, the mortality rates were not significantly different between groups. To assess whether there was any clinical impact of this apparent trend, an independent review panel that was blinded to treatment group reviewed each death. The panel found no relationship between the device and cause of death. The primary cause of death in this trial was progression of the patient's presenting illness often leading to limiting interventions. In this study, Ͼ90% of patients died after having had life-sustaining interventions withheld or withdrawn, a rate that is similar to other reports in this population (28) . The CoolGard/Cool Line catheter system was not completely effective in treating fever. Sixty-five percent of patients in the CATH group exhibited period(s) of fever Ͼ38°C. This is primarily a function of the size of the catheter. Newer catheters with a greater cooling capacity are being developed that will significantly reduce this rate.
The Cool Line catheters function appropriately in terms of their capabilities as a central catheter. There were no complications related to the use of the infusion lumens on the Cool Line. The "failure to insert" rate is low (Ͻ2.8%) and within Society of Cardiovascular and Interventional Radiologists guidelines (27) .
Minor adjustments have been made in the size of the dilator supplied and in the stiffness of the introducer wire as a result of feedback from the investigators.
In conclusion, this trial demonstrates that the use of the Alsius catheter-based cooling system results in a significant reduction in fever burden in febrile neurologic ICU patients with an appropriate risk profile. 
